Nab-paclitaxel 80 mg/m^2 clinical trials

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to previous platinum-based chemotherapy. It looks at how well adding a drug called relacorilant to nab-paclitaxel works compared to nab-paclitaxel alone.